| Literature DB >> 35334912 |
Shih-Hao Wu1,2,3, Kuan-Lin Chen3,4, Chin Hsu3, Hang-Cheng Chen1,2, Jian-Yu Chen3, Sheng-Yan Yu3, Yi-Jie Shiu3.
Abstract
Creatine supplementation is the most popular ergonomic aid for athletes in recent years and is used for improving sport performance and muscle growth. However, creatine supplementation is not always effective in all populations. To address these discrepancies, numerous studies have examined the use of creatine supplementation for muscle growth. This scoping review aimed to investigate the effects of creatine supplementation for muscle growth in various populations, in which Arksey and O'Malley's scoping review framework is used to present the findings. For this study, we performed a systematic search of the PubMed, Embase, and Web of Science databases for theses and articles published between 2012 and 2021. A manual search of the reference lists of the uncovered studies was conducted and an expert panel was consulted. Two reviewers screened the articles for eligibility according to the inclusion criteria. Methodological quality was assessed using the National Heart, Lung and Blood Institute's (NHLBI's) quality assessment tool. A total of 16 randomized controlled trials (RCTs) were finally included. All the authors extracted key data and descriptively analyzed the data. Thematic analysis was used to categorize the results into themes. Three major themes related to muscle growth were generated: (i) subjects of creatine supplementation-muscle growth is more effective in healthy young subjects than others; (ii) training of subjects-sufficient training is important in all populations; (iii) future direction and recommendation of creatine supplementation for muscle growth-injury prevention and utilization in medical practice. Overall, creatine is an efficient form of supplementation for muscle growth in the healthy young population with adequate training in a variety of dosage strategies and athletic activities. However, more well-designed, long-term RCTs with larger sample sizes are needed in older and muscular disease-related populations to definitively determine the effects of creatine supplementation on muscle growth in these other populations.Entities:
Keywords: casting; ergogenic aids; older population; performance enhancement; sarcopenia; strength
Mesh:
Substances:
Year: 2022 PMID: 35334912 PMCID: PMC8949037 DOI: 10.3390/nu14061255
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-A (PRISMA) flow diagram.
Studies recruiting healthy untrained young subjects.
| Authors | Design | QACIS Score | Participants | Creatine Dose (g/day) | Duration (Days) | Training Exercise | Evaluation Exercise | Outcome Measures | Main Findings |
|---|---|---|---|---|---|---|---|---|---|
| del Favero et al. [ | RP | 85.71 | 34 healthy | 2 × 10 g | 10 | N/A | Squat exercise | Muscle power output by a linear encoder | Muscle power output: Squat exercise: CR > PL ( |
| Kaviani et al. [ | RP | 85.71 | 18 healthy | 0.07 g/kg | 56 | Bench press | 1RM of left exercise | Check 1RM every two weeks for eight weeks | 1RM CR > PL within two weeks after bench, leg, and shoulder presses ( |
RP: randomized parallel; DB: double blind; N/A: not applicable; RM: repetition maximum; CR: creatine; PL: placebo; CK: creatine kinase.
Studies recruiting healthy trained young subjects.
| Authors | Design | QACIS Score | Participants | Creatine Dose | Duration (Days) | Training Exercise | Evaluation Exercise | Outcome Measures | Main Findings |
|---|---|---|---|---|---|---|---|---|---|
| Claudinoet al. | RP | 71.43 | 23 healthy male elite soccer player | 4 × 5 g × 7 days | 49 | Whole-body resistance training | Countermovement jump (CMJ) test | Countermovement jump test | CMJ test: CR > PL ( |
| Nunes et al. | RP | 85.71 | 43 healthy | 0.3 g/kg × 7 days | 56 | Whole-body resistance training | N/A | DXA for lean soft tissue | ↑ Lean soft tissue (LST) in upper limbs, lower limbs, and trunk, CR > PL ( |
| Yáñez-Silva et al. [ | RP | 71.43 | 20 healthy | 0.03 g/kg | 14 | Soccer training for skill development and anaerobic and aerobic performance development | Wingate anaerobic test |
Peak power output | ↑ PPO, MPO, and total work in CR vs. PL ( |
| Wang et al. [ | RP | 85.71 | 17 healthy | 4 × 5 g × 6 days | 6 | Bench row | As left | 1RM of bench row | ↑ Maximal strength, CR vs. PL ( |
| Wang et al. [ | RP | 92.86 | 30 healthy | 4 × 5 g × 6 days | 34 | Complex training: | Body composition | CMJ test | 1RM, CR > PL ( |
| Ribeiro et al. [ | RP | 85.71 | 30 healthy | 4 × 5 g × 5 days | 56 | Whole-body resistance training | N/A | Bioelectrical impedance device for ICW and ECW | ↑ Skeletal muscle |
RP: randomized parallel; DB: double blind; N/A: not applicable; RM: repetition maximum; CR: creatine; PL: placebo; ICW: intra-cellular water; ECW: extra-cellular water; CK: creatine kinase; DXA: dual-energy X-ray absorptiometry; ↑: increase; ↓: decrease.
Studies recruiting healthy mimic immobilization subjects.
| Authors | Design | QACIS Score | Participants | Creatine Dose (g/day) | Duration (Days) | Training Exercise | Evaluation Exercise | Outcome Measures | Main Findings |
|---|---|---|---|---|---|---|---|---|---|
| Fransen | RP | 92.86 | 25 healthy | 20 g | 7 | N/A | Forearm wrist flexion ergometer | Ergometry incremental protocol to fatigue and two constant load (CL1 and CL2) exercise bouts | No difference in any work and power data, after casting, CR vs. PL ( |
| Backx | RP | 92.86 | 27 healthy | 20 g × 5 days | 21 | N/A | Knee extension | Muscle biopsy | ↓ Quadricep muscle CSA after casting, no differences between groups ( |
RP: randomized parallel; DB: double blind; N/A: not applicable; RM: repetition maximum; CR: creatine; PL: placebo; ↑: increase; ↓: decrease.
Studies recruiting healthy untrained old subjects (to be continued).
| Authors et al.(Year) | Design | QACIS Score | Participants | Creatine Dose | Duration (Days) | Training Exercise | Evaluation Exercise | Outcome Measures | Main Findings |
|---|---|---|---|---|---|---|---|---|---|
| Baker et al. [ | RC | 85.71 | Nine healthy | 20 g | 1 | N/A | Leg press | 1RM | ↓ In the number of repetitions performed across sets, with no differences between CR and PL ( |
| Chami et al. [ | RP | 92.86 | 33 healthy | 0.3 g/kg | 10 | N/A | Leg press | 1RM | ↑ Muscle strength and endurance in all groups, but no difference in groups CR-H, CR-M, and PL ( |
| Candow et al. [ | RP | 92.86 | 35 healthy | 2 × 0.05 g/kg | 365 | Resistance training three times per week for one year | Chest press | Maximal strength | After 12 months of training, both groups experienced similar changes in muscle thickness and muscle strength, with no difference between CR and PL |
| Candow et al. [ | RP | 78.57 | 70 healthy | 0.1 g/kg | 365 | Resistance training three times per week for one year | N/A | pQCT | ↑ Lower leg muscle density in CR (Δ + 0.83 ± 1.15 mg·cm−3; |
RP: randomized parallel; RC: randomized crossover; DB: double blind; N/A: not applicable; RM: repetition maximum; CR: creatine; PL: placebo; DXA: dual-energy X-ray absorptiometry; pQCT: peripheral quantitative computed tomography; ↑: increase; ↓: decrease.
Studies recruiting disease-related subjects.
| Authors | Design | QACIS Score | Participants | Creatine Dose (g/day) | Duration (Days) | Training Exercise | Evaluation Exercise | Outcome Measures | Main Findings |
|---|---|---|---|---|---|---|---|---|---|
| Domingues et al. [ | RP | 85.71 | 29 symptomatic PAD | 4 × 5 g × 7 days | 56 | N/A | Six min | Functional capacity (total walking distance) was assessed by the six min walk test | No significant differences were found for function capacity (PL: Pre 389 ± 123 m vs. post-loading 413 ± 131 m vs. post-maintenance 382 ± 99 m; CR: Pre 373 ± 149 m vs. post-loading 390 ± 115 m vs. post-maintenance 369 ± 115 m, |
| Dover et al. [ | RC | 85.71 | 13 juvenile dermatomyositis males/females | < 40 kg → | 28–180 | N/A | Wingate anaerobic test | Muscle function | No significant changes in muscle function, strength, aerobic capacity, disease activity, fatigue, physical activity or quality of life in CR vs. PL |
RP: randomized parallel; RC: randomized crossover; DB: double blind; PAD: peripheral arterial disease; N/A: not applicable; CR: creatine; PL: placebo.